About 542,000 results
Any time 
Open links in new tab
Novo Nordisk, monlunabant
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
Novo Nordisk, Wegovy
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
- People also ask
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
WEB9 hours ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below …
Latest news - Novo Nordisk
WEBRead the latest news and updates from Novo Nordisk, a global healthcare company focused on diabetes and other chronic diseases. Find out about their financial results, product launches, partnerships, R&D pipeline, …
Novo Shares Fall After Mixed Safety Data on New Weight-Loss Drug
WEB10 hours ago · September 20, 2024 at 9:59 AM EDT. Save. Shares of Novo Nordisk A/Sfell after the Danish drugmaker reported mixed safety data on a molecule it’s testing …
News Details - novonordisk.com
WEB1 day ago · About Novo Nordisk. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to …
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk bets $600M biobucks on NanoVation's …
WEB2 days ago · Novo Nordisk's latest RNA deal involves $530M biobucks to sing in Korro's opera. Novo is paying an upfront fee of undisclosed size to enter into the collaboration. Factoring in milestones, the ...
News Details - Novo Nordisk
WEBMar 5, 2024 · Novo Nordisk announces positive results from FLOW trial, showing semaglutide 1.0 mg reduces the risk of kidney disease-related events by 24% in people …
Novo Nordisk signs deals worth up to $1bn with US …
WEBJan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay …
News details - Novo Nordisk
WEBNews details. 12:46 PM. June 4 2021. Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine …
Novo Nordisk trims price for blockbuster obesity drug …
WEBMay 3, 2024 · LONDON/COPENHAGEN, May 2 (Reuters) - Novo Nordisk (NOVOb.CO) raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while...
